Adiposs SA is developing ImageBAT™, a first-in-class CT contrast agent designed to non-invasively identify patients with increased risks of cancer progression and treatment failure. This technology enhances diagnostic imaging by providing critical insights into brown fat metabolism, which is linked to patient survival outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for assessing brown fat metabolism are invasive or lack the sensitivity needed for early detection of cancer progression risk and treatment failure. This limitation hinders the ability to identify patients who would benefit most from targeted therapies and personalized treatment plans.
Solution
Adiposs SA is developing ImageBAT™, a first-in-class CT contrast agent designed for non-invasive imaging of brown fat. ImageBAT™ is compatible with existing CT scanners and aims to provide clinicians with a tool to identify patients at increased risk of cancer progression, treatment failure, and shorter survival. By quantifying brown fat activity, ImageBAT™ seeks to enable earlier and more informed clinical decision-making in oncology and metabolic diseases. The technology has completed Phase I clinical trials, demonstrating its safety profile and potential for broad clinical application.
Target Audience
The primary target audience includes oncologists, radiologists, and medical professionals involved in the diagnosis and treatment of cancer and metabolic disorders.
Features
- First-in-class CT contrast agent specifically targeting brown fat
- Non-invasive assessment of brown fat metabolism using standard CT scanners
- Potential applications in oncology, metabolic diseases, and amyotrophic lateral sclerosis (ALS)
- Completed Phase I clinical trial demonstrating safety